Skip to main content
Top
Published in: Diabetologia 1/2006

01-01-2006 | Article

Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin

Authors: J. L. Chan, V. Stoyneva, T. Kelesidis, P. Raciti, C. S. Mantzoros

Published in: Diabetologia | Issue 1/2006

Login to get access

Abstract

Aims/hypothesis

Peptide YY (PYY) is a gut-derived hormone that has been shown to reduce short-term food intake in animals and humans. It has been proposed that deficiency of PYY contributes to obesity in humans. However, the physiology of PYY regulation by factors such as caloric restriction, or by other molecules important in energy homeostasis, e.g. leptin, remains to be fully elucidated.

Materials and methods

We evaluated the effect on PYY levels of: (1) caloric ingestion (a mixed meal) in five healthy normal-weight subjects; (2) fasting for 2 or 3 days in eight lean men and seven lean women respectively; and (3) recombinant human leptin administration at physiological replacement and pharmacological doses.

Results

PYY levels increased 50% after a mixed meal (p=0.01), and short-term complete fasting for 2 or 3 days decreased leptin and PYY levels to 20–30% and 40–60% of baseline, respectively (both p<0.05). However, recombinant human leptin administration at physiological doses to restore the fasting-induced decrease of leptin levels and at pharmacological doses over the short term had no effect on PYY levels.

Conclusions/interpretation

PYY increases after meal ingestion and decreases after fasting in a manner consistent with a meal-related signal of energy homeostasis. Importantly, circulating levels of this gut-secreted molecule are independent of regulation by leptin over the short term. These findings contribute towards our understanding of the homeostatic systems that regulate appetite in humans, including the possible redundancy of gastrointestinally secreted and adipocyte-secreted signals. This may be of importance for the future development of medications to treat obesity.
Literature
1.
go back to reference Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef
2.
go back to reference Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S (2003) Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919PubMedCrossRef Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S (2003) Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919PubMedCrossRef
3.
go back to reference Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349:941–948PubMedCrossRef Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med 349:941–948PubMedCrossRef
4.
go back to reference Tschop M, Castaneda TR, Joost HG et al (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430:1PubMedCrossRef Tschop M, Castaneda TR, Joost HG et al (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430:1PubMedCrossRef
5.
go back to reference Korner J, Bessler M, Cirilo LJ et al (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359–365PubMedCrossRef Korner J, Bessler M, Cirilo LJ et al (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359–365PubMedCrossRef
6.
go back to reference Mantzoros CS (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130:671–680PubMed Mantzoros CS (1999) The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 130:671–680PubMed
7.
go back to reference Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed
8.
go back to reference Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 111:1409–1421PubMedCrossRef Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 111:1409–1421PubMedCrossRef
9.
go back to reference Chan JL, Moschos SJ, Bullen J et al (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-α receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90: 1625–1631PubMedCrossRef Chan JL, Moschos SJ, Bullen J et al (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-α receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90: 1625–1631PubMedCrossRef
10.
go back to reference Wong SL, DePaoli AM, Lee JH, Mantzoros CS (2004) Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab 89:2672–2677PubMedCrossRef Wong SL, DePaoli AM, Lee JH, Mantzoros CS (2004) Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. J Clin Endocrinol Metab 89:2672–2677PubMedCrossRef
11.
go back to reference Alvarez BM, Borque M, Martinez-Sarmiento J et al (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12:324–327CrossRef Alvarez BM, Borque M, Martinez-Sarmiento J et al (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12:324–327CrossRef
12.
go back to reference Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295PubMedCrossRef Considine RV, Sinha MK, Heiman ML et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295PubMedCrossRef
13.
go back to reference Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575PubMedCrossRef Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575PubMedCrossRef
14.
go back to reference Chan JL, Bullen J, Lee JH, Yiannakouris N, Mantzoros CS (2004) Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab 89:335–343PubMedCrossRef Chan JL, Bullen J, Lee JH, Yiannakouris N, Mantzoros CS (2004) Ghrelin levels are not regulated by recombinant leptin administration and/or three days of fasting in healthy subjects. J Clin Endocrinol Metab 89:335–343PubMedCrossRef
15.
go back to reference Kiely JM, Graewin SJ, Pitt HA, Swartz-Basile DA (2005) Leptin increases small intestinal response to cholecystokinin in leptin-deficient obese mice. J Surg Res 124:146–150PubMedCrossRef Kiely JM, Graewin SJ, Pitt HA, Swartz-Basile DA (2005) Leptin increases small intestinal response to cholecystokinin in leptin-deficient obese mice. J Surg Res 124:146–150PubMedCrossRef
16.
go back to reference Troupin B, Lush C, Chen K et al (2005) A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3–36) in lean and obese subjects. Endocrine Society Meeting, 4–7 June, 2005, San Diego: oral presentation (Abstract) Troupin B, Lush C, Chen K et al (2005) A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3–36) in lean and obese subjects. Endocrine Society Meeting, 4–7 June, 2005, San Diego: oral presentation (Abstract)
Metadata
Title
Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin
Authors
J. L. Chan
V. Stoyneva
T. Kelesidis
P. Raciti
C. S. Mantzoros
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0041-2

Other articles of this Issue 1/2006

Diabetologia 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine